Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial-Reference-Cited by-同舟云学术

Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial

Published:2024-08-29 Issue: Volume: Page:
ISSN:0028-1298
Container-title:Naunyn-Schmiedeberg's Archives of Pharmacology
language:en
Short-container-title:Naunyn-Schmiedeberg's Arch Pharmacol

Author:

Sanei Zahra Sadat,Shahrahmani Fatemeh,Khaleghi Manesh Behrooz,Hamidi-alamdari Daryoush,Mehrad-Majd Hassan,Mavaji Darban Behzad,Mirdoosti Seyedeh Motahareh,Seddigh-Shamsi Mohsen

Funder

Mashhad University of Medical Sciences

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00210-024-03371-6.pdf

Reference47 articles.

1. A. N. Al Balawi et al., "Perceptions of medicinal herbal products during the COVID-19 pandemic period among Saudi patients: a cross-sectional study," Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 397, no. 1, pp. 497–506, 2024, https://doi.org/10.1007/s00210-023-02610-6

2. D. H. Alamdari et al., "Methylene blue for treatment of hospitalized COVID-19 patients, randomized, controlled, open-label clinical trial, Phase 3," Aristotle Biomedical Journal, vol. 3, no. 2, pp. 1–7, 2021, https://doi.org/10.24875/ric.21000028.

3. Al-Tawfiq JA, Temsah M-H (2023) Perspective on the challenges of COVID-19 facing healthcare workers. Infection 51(2):541–544. https://doi.org/10.1007/s15010-022-01882-z

4. Aslan A, Aslan C, Zolbanin NM, Jafari R (2021) Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management. Pneumonia 13(1):14. https://doi.org/10.1186/s41479-021-00092-9

5. Bellani G et al (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315(8):788–800. https://doi.org/10.1001/jama.2016.0291